The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Quercetin improves nonalcoholic fatty liver by ameliorating inflammation, oxidative stress, and lipid metabolism in db/db mice
Abstract
Multiphase pathological processes involve in Type 2 diabetes (T2DM)‐induced nonalcoholic fatty liver disease (NAFLD). However, the therapies are quite limited. In the present study, the hepatoprotective effects and underlying mechanisms of quercetin in T2DM‐induced NAFLD were investigated. T2DM‐induced NAFLD and quercetin treatment models were established in vivo and in vitro. The results revealed that quercetin alleviated serum transaminase levels and markedly reduced T2DM‐induced histological alterations of livers. Additionally, quercetin restored superoxide dismutase, catalase, and glutathione content in livers. Not only that, quercetin markedly attenuated T2DM‐induced production of interleukin 1 beta, interleukin 6, and TNF‐α. Accompanied by the restoration of the increased serum total bile acid (p = .0001) and the decreased liver total bile acid (p = .0005), quercetin could reduce lipid accumulation in the liver of db/db mice. Further mechanism studies showed that farnesoid X receptor 1/Takeda G‐protein‐coupled receptor 5 signaling pathways was involved in quercetin regulation of lipid metabolism in T2DM‐induced NAFLD. In high D‐glucose and free fatty acid cocultured HepG2 cells model, quercetin eliminated lipid droplets and restored the upregulated total cholesterol and triglyceride levels. Similar to the findings in mice, quercetin could also activate farnesoid X receptor 1/Takeda G‐protein‐coupled receptor 5 signaling pathway. These findings suggested that quercetin might be a potentially effective drug for the treatment of T2DM‐induced NAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms of Diabetic Complications
Forbes, J. M., & Cooper, M. E. (2013) · Physiological Reviews · doi:10.1152/physrev.00045.2011 · Cited by 2,890
Health effects of quercetin: From antioxidant to nutraceutical
Boots, A. W., Haenen, G. R. M. M., & Bast, A. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.03.008 · Cited by 2,121
Chávez-Talavera, O., Tailleux, A., Lefebvre, P., & Staels, B. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.01.055 · Cited by 970
Bile acid signaling in metabolic disease and drug therapy
Li, T., & Chiang, J. Y. L. (2014) · Pharmacological Reviews · doi:10.1124/pr.113.008201 · Cited by 935
Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases
Samuel, V. T., & Shulman, G. I. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.08.002 · Cited by 745 · cited 1×
“A growing evidence supports the same pathogenesis in the development and progression of T2DM and NAFLD, including hyperglycemia, oxidative stress, cellular inflammatory factors, and insulin resistance (Gao & Tsukamoto, 2016; Haas, Francque, & Staels, 2016; Samuel & Shulman, 2018).”
BackgroundSystemic gut microbial modulation of bile acid metabolism in host tissue compartments
Swann, J. R., Want, E. J., Geier, F. M., Spagou, K., Wilson, I. D., Sidaway, J. E., Nicholson, J. K., & Holmes, E. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1006734107 · Cited by 726
The flavonoid quercetin in disease prevention and therapy: Facts and fancies
Russo, M., Spagnuolo, C., Tedesco, I., Bilotto, S., & Russo, G. L. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.08.010 · Cited by 698
Targeting inflammation in the treatment of type 2 diabetes: time to start
Donath, M. Y. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4275 · Cited by 690
Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease
Masarone, M., Rosato, V., Dallio, M., Gravina, A. G., Aglitti, A., Loguercio, C., Federico, A., & Persico, M. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/9547613 · Cited by 648
Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-analysis
Mantovani, A., Byrne, C. D., Bonora, E., & Targher, G. (2018) · Diabetes Care · doi:10.2337/dc17-1902 · Cited by 624
Pathak, P., Xie, C., Nichols, R. G., Ferrell, J. M., Boehme, S., Krausz, K. W., Patterson, A. D., Gonzalez, F. J., & Chiang, J. Y. L. (2018) · Hepatology · doi:10.1002/hep.29857 · Cited by 567
Porras, D., Nistal, E., Martínez-Flórez, S., Pisonero-Vaquero, S., Olcoz, J. L., Jover, R., González-Gallego, J., García-Mediavilla, M. V., & Sánchez-Campos, S. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.11.037 · Cited by 524
Therapeutic potential of quercetin as a cardiovascular agent
Patel, R. V., Mistry, B. M., Shinde, S. K., Syed, R., Singh, V., & Shin, H.-S. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.06.053 · Cited by 504
Role of bile acids in metabolic control
Molinaro, A., Wahlström, A., & Marschall, H.-U. (2018) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2017.11.002 · Cited by 447
Pathophysiology and Mechanisms of Nonalcoholic Fatty Liver Disease
Haas, J. T., Francque, S., & Staels, B. (2016) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021115-105331 · Cited by 394
FXR: a metabolic regulator and cell protector
Wang, Y.-D., Chen, W.-D., Moore, D. D., & Huang, W. (2008) · Cell Research · doi:10.1038/cr.2008.289 · Cited by 389
Oxidative Stress as a Critical Factor in Nonalcoholic Fatty Liver Disease Pathogenesis
Spahis, S., Delvin, E., Borys, J.-M., & Levy, E. (2017) · Antioxidants & Redox Signaling · doi:10.1089/ars.2016.6776 · Cited by 386
Altered Bile Acid Metabolome in Patients with Nonalcoholic Steatohepatitis
Ferslew, B. C., Xie, G., Johnston, C. K., Su, M., Stewart, P. W., Jia, W., Brouwer, K. L. R., & Sidney Barritt, A. (2015) · Digestive Diseases and Sciences · doi:10.1007/s10620-015-3776-8 · Cited by 335
A vicious circle between insulin resistance and inflammation in nonalcoholic fatty liver disease
Chen, Z., Yu, R., Xiong, Y., Du, F., & Zhu, S. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0572-9 · Cited by 316
Shi, G.-J., Li, Y., Cao, Q.-H., Wu, H.-X., Tang, X.-Y., Gao, X.-H., Yu, J.-Q., Chen, Z., & Yang, Y. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.10.130 · Cited by 299
Hu, K., Miao, L., Goodwin, T. J., Li, J., Liu, Q., & Huang, L. (2017) · ACS Nano · doi:10.1021/acsnano.7b01522 · Cited by 292
Inflammation in Alcoholic and Nonalcoholic Fatty Liver Disease: Friend or Foe?
Gao, B., & Tsukamoto, H. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.025 · Cited by 287
Jeong, S.-M., Kang, M.-J., Choi, H.-N., Kim, J.-H., & Kim, J.-I. (2012) · Nutrition Research and Practice · doi:10.4162/nrp.2012.6.3.201 · Cited by 265
Microbial impact on cholesterol and bile acid metabolism: current status and future prospects
Kriaa, A., Bourgin, M., Potiron, A., Mkaouar, H., Jablaoui, A., Gérard, P., Maguin, E., & Rhimi, M. (2019) · Journal of Lipid Research · doi:10.1194/jlr.r088989 · Cited by 264
Metabolomic identification of subtypes of nonalcoholic steatohepatitis
Alonso, C., Fernández-Ramos, D., Varela-Rey, M., Martínez-Arranz, I., Navasa, N., Van Liempd, S. M., Lavín Trueba, J. L., Mayo, R., Ilisso, C. P., de Juan, V. G., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.01.015 · Cited by 263
Yaribeygi, H., Atkin, S. L., & Sahebkar, A. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27164 · Cited by 243
Videla, L. A., Rodrigo, R., Araya, J., & Poniachik, J. (2004) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2004.06.033 · Cited by 239
The Beneficial Effects of Quercetin, Curcumin, and Resveratrol in Obesity
Zhao, Y., Chen, B., Shen, J., Wan, L., Zhu, Y., Yi, T., & Xiao, Z. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/1459497 · Cited by 212
Actions of Quercetin, a Polyphenol, on Blood Pressure
Marunaka, Y., Marunaka, R., Sun, H., Yamamoto, T., Kanamura, N., Inui, T., & Taruno, A. (2017) · Molecules · doi:10.3390/molecules22020209 · Cited by 176
Antidiabetic effect of quercetin: A systematic review and meta-analysis of animal studies
Bule, M., Abdurahman, A., Nikfar, S., Abdollahi, M., & Amini, M. (2019) · Food and Chemical Toxicology · doi:10.1016/j.fct.2019.01.037 · Cited by 167
Lü, Q., Ji, X., Zhou, Y., Yao, X., Liu, Y., Zhang, F., & Yin, X. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.06.006 · Cited by 161
Self-citationYang, T., Shu, T., Liu, G., Mei, H., Zhu, X., Huang, X., Zhang, L., & Jiang, Z. (2017) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2017.05.015 · Cited by 146
Self-citationNatural products as modulators of the nuclear receptors and metabolic sensors LXR, FXR and RXR
Hiebl, V., Ladurner, A., Latkolik, S. L., & Dirsch, V. M. (2018) · Biotechnology Advances · doi:10.1016/j.biotechadv.2018.03.003 · Cited by 145
Wang, Z., Zhai, D., Zhang, D., Bai, L., Yao, R., Yu, J., Cheng, W., & Yu, C. (2016) · Reproductive Sciences · doi:10.1177/1933719116667218 · Cited by 133
Pisonero‐Vaquero, S., Martínez‐Ferreras, Á., García‐Mediavilla, M. V., Martínez‐Flórez, S., Fernández, A., Benet, M., Olcoz, J. L., Jover, R., González‐Gallego, J., & Sánchez‐Campos, S. (2015) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201400913 · Cited by 128
Crosstalk between nonalcoholic fatty liver disease and cardiometabolic syndrome
Lim, S. K., Taskinen, M., & Borén, J. (2018) · Obesity Reviews · doi:10.1111/obr.12820 · Cited by 111
Iracheta‐Vellve, A., Calenda, C. D., Petrášek, J., Ambade, A., Kodys, K., Adorini, L., & Szabó, G. (2018) · Hepatology Communications · doi:10.1002/hep4.1256 · Cited by 107
Lü, Q., Wang, W., Zhang, M., Ma, Z., Qiu, X., Shen, M., & Yin, X. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.7014 · Cited by 99
Self-citationLow molecular weight fucoidan attenuates liver injury via SIRT1/AMPK/PGC1α axis in db/db mice
Zheng, Y., Liu, T., Wang, Z., Xu, Y., Zhang, Q., & Luo, D. (2018) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2018.02.072 · Cited by 98
Mann, J. P., Vito, R. D., Mosca, A., Alisi, A., Armstrong, M. J., Raponi, M., Baumann, U., & Nobili, V. (2015) · Hepatology · doi:10.1002/hep.28374 · Cited by 97
Liu, Y., Liu, X., Kong, L., Zhang, M., Chen, Y., Xia Shuang, Z. H. U., & Hao, Y. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.11.066 · Cited by 88
Eitah, H. E., Maklad, Y. A., Abdelkader, N. F., el Din, A. A. G., Badawi, M., & Kenawy, S. A. (2018) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2018.12.011 · Cited by 87
Latifi, E., Mohammadpour, A. A., Hafshejani, B. F., & Nourani, H. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.10.152 · Cited by 80
Goedeke, L., Perry, R. J., & Shulman, G. I. (2019) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104727 · Cited by 79
Samadder, A., Chakraborty, D., De, A. K., Bhattacharyya, S. S., Bhadra, K., & Khuda‐Bukhsh, A. R. (2011) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2011.07.012 · Cited by 75
Zhu, M., Zhou, X., & Zhao, J. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.5329 · Cited by 72
Gaballah, H. H., Zakaria, S. S., Mwafy, S. E., Tahoon, N., & Ebeid, A. M. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.05.086 · Cited by 71
Maciel, R. M., Costa, M. M., Martins, D. B., França, R. T., Schmatz, R., Graça, D. L., Duarte, M. M. M. F., Danesi, C. C., Mazzanti, C. M. D. A., Schetinger, M. R. C., et al. (2013) · Research in Veterinary Science · doi:10.1016/j.rvsc.2013.04.028 · Cited by 70
Lü, Q., Hao, M., Wu, W., Zhang, N., Isaac, A. T., Yin, J., Zhu, X., Du, L., & Yin, X. (2017) · Acta Biochimica Polonica · doi:10.18388/abp.2016_1387 · Cited by 70
Self-citationFerrell, J. M., Pathak, P., Boehme, S., Gilliland, T., & Chiang, J. Y. L. (2019) · Hepatology · doi:10.1002/hep.30513 · Cited by 65
Bile acid homeostasis paradigm and its connotation with cholestatic liver diseases
Yang, T., Khan, G. J., Wu, Z., Wang, X., Zhang, L., & Jiang, Z. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.09.007 · Cited by 65
Self-citationYang, Z., Zhu, M., Zhang, Y., Wen, B., An, H., Ou, X., Xiong, Y., Lin, H., Liu, Z., & Huang, J. (2019) · Phytotherapy Research · doi:10.1002/ptr.6295 · Cited by 63
The mTOR promotes oxidative stress-induced apoptosis of mesangial cells in diabetic nephropathy
Lü, Q., Zhou, Y., Hao, M., Li, C., Wang, J., Shu, F., Du, L., Zhu, X., Zhang, Q., & Yin, X. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.12.012 · Cited by 60
Self-citationBile acid regulation: A novel therapeutic strategy in non-alcoholic fatty liver disease
Yu, Q., Jiang, Z., & Zhang, L. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.04.005 · Cited by 56
Self-citationHuang, X., Sun, M., Li, D., Liu, J., Guo, H., Dong, Y., Jiang, L., Pan, Q., Man, Y., Wang, S., et al. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2010.12.026 · Cited by 54
Xia, Y., Li, Q., Zhong, W., Dong, J., Wang, Z., & Wang, C. (2011) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-3-31 · Cited by 53
Cialdella-Kam, L. A., Ghosh, S., Meaney, M., Knab, A. M., Shanely, R. A., & Nieman, D. C. (2017) · Nutrients · doi:10.3390/nu9070773 · Cited by 52
Yang, T., Mei, H., Xu, D., Zhou, W., Zhu, X., Sun, L., Huang, X., Wang, X., Shu, T., Liu, J., et al. (2017) · Food and Chemical Toxicology · doi:10.1016/j.fct.2017.09.051 · Cited by 45
Self-citationVanjiappan, S., Hamide, A., Ananthakrishnan, R., Periyasamy, S. G., & Mehalingam, V. (2018) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2018.01.001 · Cited by 45
Goodarzi, R., Sabzian, K., Shishehbor, F., & Mansoori, A. (2019) · Phytotherapy Research · doi:10.1002/ptr.6270 · Cited by 45
Daniel, O. O., Adeoye, A. O., Ojowu, J., & Olorunsogo, O. O. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.08.114 · Cited by 42
Xia Shuang, Z. H. U., Cheng, Y., Lü, Q., Du, L., Yin, X., & Liu, Y. (2018) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-018-1543-z · Cited by 40
Self-citationZhao, H., Song, X., Li, Z., & Wang, X. (2018) · Medicine · doi:10.1097/md.0000000000012356 · Cited by 36
Cao, X., Song, L., Zhang, Y., Li, Q., Shi, T., Yang, F., Yuan, M.-X., Zhong, X., & Yang, J. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3123 · Cited by 36
Han, D.-N., Zhang, D., Wang, L., & Zhang, Y. (2013) · Peptides · doi:10.1016/j.peptides.2013.03.028 · Cited by 27
Zhang, Y., Dong, H., Wang, M., & Zhang, J. (2016) · Journal of Diabetes Research · doi:10.1155/2016/8492780 · Cited by 27
Raschi, E., Mazzotti, A., Poluzzi, E., Ponti, F. D., & Marchesini, G. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1531126 · Cited by 27
Seo, E., Oh, Y. S., & Jun, H. (2016) · Nutrients · doi:10.3390/nu8020083 · Cited by 26
Liu, Y., Song, A., Yang, X., Zhen, Y., Chen, W., Yang, L., Wang, C., & Ma, H. (2018) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2018.3715 · Cited by 25
Zhu, Y., Teng, T., Wang, H., Guo, H., Du, L., Yang, B., Yin, X., & Sun, Y. (2017) · Food & Function · doi:10.1039/c7fo01253e · Cited by 21
Self-citationMoh, M. A. M., Jung, C., Lee, B., Choi, D., Kim, B., Kim, C., Kang, S., & Mok, J. (2018) · Diabetes and Vascular Disease Research · doi:10.1177/1479164118810691 · Cited by 17
Zhou, C., Xiang, M., Shu-ying, H., & Qian, Z. (2009) · Phytotherapy Research · doi:10.1002/ptr.3039 · Cited by 16
Liu, J., Zhao, Y., Huang, C., Li, Y., & Guo, F. (2019) · Phytotherapy Research · doi:10.1002/ptr.6374 · Cited by 15
Wang, D. Q. ‐., Neuschwander‐Tetri, B. A., Portincasa, P., & Pandak, W. M. (2012) · Journal of Lipids · doi:10.1155/2012/560715 · Cited by 10
Cited by
Zhou, H., Ma, C., Wang, C., Gong, L., Zhang, Y., & Li, Y. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.173976 · Cited by 73
Metadata
- Authors
- Yang, H., Yang, T., Heng, C., Zhou, Y., Jiang, Z., Qian, X., Du, L., Mao, S., Yin, X., & Lu, Q.
- Venue
- Phytotherapy Research
- Publisher
- Wiley
- Published
- 2019-08-26
- Volume
- 33
- Issue
- 12
- Pages
- 3140-3152
- ISSN
- 0951-418X (ISSN-L)
- 1099-1573
- OpenAlex
- W2970026022
- Cited by
- 275
- References
- 74
- FWCI
- 14.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.